Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
Nogami N, Barlesi F, Socinski MA, Reck M, Thomas CA, Cappuzzo F, Mok TSK, Finley G, Aerts JG, Orlandi F, Moro-Sibilot D, Jotte RM, Stroyakovskiy D, Villaruz LC, Rodríguez-Abreu D, Wan-Teck Lim D, Merritt D, Coleman S, Lee A, Shankar G, Yu W, Bara I, Nishio M. Nogami N, et al. J Thorac Oncol. 2022 Feb;17(2):309-323. doi: 10.1016/j.jtho.2021.09.014. Epub 2021 Oct 7. J Thorac Oncol. 2022. PMID: 34626838 Free article. Clinical Trial.
Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors.
Barlési F, Balleyguier C, Besse B, Bonodeau F, Brenac F, Corneloup O, Dansin E, Ferretti G, Gaubert JY, Gervais R, Lacombe C, Loundou A, Moro-Sibilot D, Planchard D, Scherpereel A, Menu Y. Barlési F, et al. Ann Oncol. 2010 Aug;21(8):1682-1686. doi: 10.1093/annonc/mdp590. Epub 2010 Jan 11. Ann Oncol. 2010. PMID: 20064831 Free article.
Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
Pluquet E, Cadranel J, Legendre A, Faller MB, Souquet PJ, Zalcman G, Perol M, Fraboulet G, Oliveiro G, De Fraipont F, Quoix E, Lantuejoul S, Milleron B, Moro-Sibilot D. Pluquet E, et al. J Thorac Oncol. 2010 Apr;5(4):491-6. doi: 10.1097/JTO.0b013e3181cf0440. J Thorac Oncol. 2010. PMID: 20195171 Free article.
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).
Morère JF, Bréchot JM, Westeel V, Gounant V, Lebeau B, Vaylet F, Barlési F, Urban T, Souquet PJ, Debieuvre D, Baudrin L, Zalcman G, Morin F, Milleron B, Moro-Sibilot D. Morère JF, et al. Lung Cancer. 2010 Dec;70(3):301-7. doi: 10.1016/j.lungcan.2010.03.003. Epub 2010 Apr 18. Lung Cancer. 2010. PMID: 20400201 Clinical Trial.
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
Duruisseaux M, Baudrin L, Quoix E, Wislez M, Moro-Sibilot D, Coëtmeur D, Monnet I, Mourlanette P, Morère JF, Soria JC, Westeel V, Morin F, Cadranel J. Duruisseaux M, et al. J Thorac Oncol. 2012 Sep;7(9):1423-31. doi: 10.1097/JTO.0b013e31825ab897. J Thorac Oncol. 2012. PMID: 22767177 Free article. Clinical Trial.
Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME).
Schnabel PA, Smit E, Carpeño Jde C, Leśniewski-Kmak K, Aerts J, Kraaij K, Visseren-Grul C, Dyachkova Y, Taipale K, Girvan A, Moro-Sibilot D. Schnabel PA, et al. Lung Cancer. 2012 Dec;78(3):263-9. doi: 10.1016/j.lungcan.2012.09.001. Epub 2012 Oct 4. Lung Cancer. 2012. PMID: 23040326 Clinical Trial.
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O. Mazières J, et al. J Clin Oncol. 2013 Jun 1;31(16):1997-2003. doi: 10.1200/JCO.2012.45.6095. Epub 2013 Apr 22. J Clin Oncol. 2013. PMID: 23610105
Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer.
Vignot S, Frampton GM, Soria JC, Yelensky R, Commo F, Brambilla C, Palmer G, Moro-Sibilot D, Ross JS, Cronin MT, André F, Stephens PJ, Lazar V, Miller VA, Brambilla E. Vignot S, et al. J Clin Oncol. 2013 Jun 10;31(17):2167-72. doi: 10.1200/JCO.2012.47.7737. Epub 2013 Apr 29. J Clin Oncol. 2013. PMID: 23630207
Customized adjuvant phase II trial in patients with non-small-cell lung cancer: IFCT-0801 TASTE.
Wislez M, Barlesi F, Besse B, Mazières J, Merle P, Cadranel J, Audigier-Valette C, Moro-Sibilot D, Gautier-Felizot L, Goupil F, Renault A, Quoix E, Souquet PJ, Madroszyck A, Corre R, Pérol D, Morin F, Zalcman G, Soria JC. Wislez M, et al. J Clin Oncol. 2014 Apr 20;32(12):1256-61. doi: 10.1200/JCO.2013.53.1525. Epub 2014 Mar 17. J Clin Oncol. 2014. PMID: 24638013 Clinical Trial.
248 results